aTyr Pharma (ATYR)
Develops efzofitimod and tRNA-synthetase-derived therapies for fibrosis and inflammation.
Something off on this page? Send us feedback.
Builds therapies from extracellular tRNA synthetase biology, led by efzofitimod for pulmonary sarcoidosis and systemic-sclerosis-associated ILD. The pre-commercial business centers on clinical development, with Kyorin holding Japanese rights to efzofitimod.
Uses a proprietary library of domains from all 20 tRNA synthetases to identify signaling pathways for fibrosis and inflammation therapies. Its lead program, efzofitimod, is a biologic immunomodulator being developed for pulmonary sarcoidosis and systemic-sclerosis-associated ILD.
Clinical development remains the operating focus, supported in Japan by Kyorin's licensed development and commercialization rights for efzofitimod. The organization is U.S.-based, with most full-time staff in R&D, clinical, manufacturing, and regulatory roles.
EFZO-FIT missed its primary endpoint in 2025, and further progress depends on acceptable safety and efficacy, regulatory alignment, clinical-material manufacturing, intellectual-property protection, and additional funding.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 20, 2026 | Freedom Broker | Upgrade | ||
| Sep 16, 2025 | Wells Fargo | Downgrade | ||
| Sep 16, 2025 | RBC Capital | Downgrade | ||
| Sep 15, 2025 | Leerink Partners | Downgrade | Target: — | Target: $1 |
| Sep 15, 2025 | HC Wainwright & Co. | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $57.4M · Total debt $11.3M · Total assets $69.8M · Shareholders' equity $48.8M
- Revenue
- $0
- Operating income
- −$10.9M
- Net income
- −$10.3M
No dividends on record.
| Insiders | 1.03% | 1.01M shares | |
|---|---|---|---|
| 5 holders · as of May 28, 2026 | |||
| Strategic holders | 22.68% | 22.24M shares | |
| 3 holders · as of Jun 5, 2026 | |||
| Other | 76.29% | 74.83M shares | |
| remainder | |||
98.09M company shares as of Sep 23, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Federated Hermes, Inc.Strategic | 10.75% | 10.54M | filed Oct 7, 2025 |
FMR LLCStrategic | 6.05% | 5.94M | filed Jun 5, 2026 |
BlackRock, Inc.Strategic | 5.88% | 5.76M | filed Jul 17, 2025 |
Paul SchimmelInsiderdirector | 0.79% | 779,143 | filed May 28, 2026 |
Sanjay ShuklaInsiderdirector, officer: President and CEO | 0.16% | 153,553 | filed Feb 4, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 27, 2026 | Paul Schimmel | director | +100,000 | $0.4963 |
| Feb 4, 2026 | Nancy Denyes | officer: General Counsel | −1,118 | $0.9761 |
| Feb 4, 2026 | Jill Marie Broadfoot | officer: Chief Financial Officer | −1,558 | $0.9760 |
| Feb 4, 2026 | Sanjay Shukla | director, officer: President and CEO | −3,745 | $0.9760 |
| Oct 8, 2025 | Paul Schimmel | director | +682,001 | $0.8980 |
